Peripheral Vascular Devices Industry, Global, 2024–2029

Report Summary: Peripheral Vascular Devices Market, Global, 2024–2029

The global peripheral vascular devices market size was valued at USD 4.33 billion in 2024 and is projected to reach USD 6.06 billion by 2029, expanding at a CAGR of 6.9% during the forecast period. Growth is driven by rising peripheral artery disease (PAD) cases, increasing adoption of minimally invasive endovascular procedures, and strong advancements in drug-eluting technologies across global vascular care settings. The expanding shift toward outpatient and office-based vascular interventions further accelerates device demand in the global peripheral vascular device market.

Key Market Trends & Insights

• North America accounted for the largest revenue share of the peripheral vascular devices market in 2024.
• Drug-eluting stents (DES) represented the leading product segment, contributing 38.3% of global revenue in 2024.
• Drug-coated balloons (DCB) are expected to be the fastest-growing product category through 2029, supported by rising adoption of sirolimus-based balloons.
• Asia Pacific is projected to register the highest CAGR (9.3%), driven by improving PAD diagnosis rates and expanding healthcare infrastructure.
• Increasing shift toward outpatient and office-based laboratories (OBLs) continue to accelerate demand within the peripheral interventions market.
• Rapid innovation in bioresorbable scaffolds and next-generation vessel preparation technologies is reshaping long-term treatment strategies for complex PAD cases.

Market Size & Forecast

• 2024 Market Size: USD 4.33 Billion
• 2029 Projected Market Size: USD 6.06 Billion
• CAGR (2024–2029): 6.9%
• North America: Largest regional market in 2024
• Asia Pacific: Fastest-growing regional market (CAGR 9.3%)

The rising prevalence of PAD and strong demand for minimally invasive endovascular treatments are accelerating growth in the global peripheral vascular device market. Advancements in drug-delivery platforms, vascular imaging, and bioresorbable scaffolds are improving outcomes, while expanding access to vascular specialists in India, China, Brazil, and Southeast Asia supports wider adoption. The continued rise of outpatient vascular centers and OBLs is expected to further strengthen the global peripheral interventions market.

Competitor Landscape Summary:

The market is led by Boston Scientific, Abbott, Medtronic, BD/Bard, and Terumo, which together hold the majority share due to broad portfolios and strong clinical data. Emerging players—such as Concept Medical, Shockwave Medical, NexStep Medical, and R3 Vascular—are gaining traction with sirolimus-based drug systems, IVL technologies, and bioresorbable scaffolds. Companies offering advanced drug-delivery and vessel-preserving solutions are positioned to gain competitive advantage through 2029.

Market Overview & Trends: Peripheral Vascular Devices Market, Global, 2024–2029

The peripheral vascular devices market is experiencing a transformative phase that stems from the convergence of clinical needs, technological advancements, and evolving patient care ecosystems. Peripheral artery disease affects over 200 million individuals worldwide, yet remains significantly underdiagnosed, particularly in developing markets. This underdiagnosis creates a substantial treatment gap, which in turn contributes to rising demand for endovascular devices capable of restoring blood flow in obstructed vessels. Alongside this growing patient pool, there has been a clear shift toward minimally invasive vascular procedures, which now dominate PAD treatment strategies, especially in developed countries. In the United States, for instance, more than 81% of peripheral interventions are performed using endovascular techniques rather than open surgical approaches, underscoring the procedure’s clinical advantages and patient preferences 

Technologically, the peripheral interventions market has shifted decisively toward advanced drug-delivery platforms such as drug-eluting stents (DES) and drug-coated balloons (DCB). These devices offer superior safety and efficacy outcomes, including reduced restenosis and improved long-term patency. The increasing availability of sirolimus-based coatings and polymer-free drug-eluting designs demonstrates the market’s pivot toward improved vessel healing responses. Additionally, the U.S. FDA’s 2023 update confirming no excess mortality risk associated with paclitaxel-coated devices contributed to revitalizing confidence in DCB and DES systems, thereby accelerating global adoption.

Another major trend involves substantial investment in bioresorbable scaffolds, with leading manufacturers developing dissolving stent platforms aimed particularly at BTK lesion management. These scaffolds are designed to deliver mechanical support and targeted drug therapy before gradually resorbing within the body, reducing the need for future interventions. Complementing these innovations, robotic-assisted peripheral interventions are gaining early momentum, albeit from a small base, due to the promise of improved precision, reduced radiation exposure for clinicians, and enhanced procedural efficiency.

Finally, the migration of vascular procedures from inpatient hospital environments to outpatient and office-based laboratories, especially in North America, represents an important trend that is reshaping the economics and growth trajectory of the peripheral vascular device market. These outpatient settings offer lower procedure costs, shorter patient stays, and more favorable reimbursement structures, making them a strong expansion catalyst for the overall market.

Revenue & Spending Forecast: Peripheral Vascular Devices Market, Global, 2024–2029

The global peripheral vascular devices market is projected to maintain a strong and steady growth trajectory throughout the forecast period, supported by rising endovascular procedure volumes, expanding clinical validation, and increasing adoption of advanced drug-delivery technologies. Market revenues reached USD 4.33 billion in 2024 and are expected to increase to USD 6.06 billion by 2029, reflecting a sustained CAGR of 6.9%. This upward momentum is reinforced by growing prevalence of peripheral artery disease (PAD), expanding use of drug-eluting technologies, and the continued shift toward minimally invasive therapy approaches across global vascular care pathways. The combination of clinical innovation, expanding physician adoption, and broader patient access ensures durable revenue growth through 2029.

Scope of Analysis: Peripheral Vascular Devices Market, Global, 2024–2029

This analysis examines the global peripheral vascular devices market across device categories, end-user segments, care settings, and major geographic regions. The study focuses on devices used for diagnosing and treating peripheral artery disease across multiple anatomic locations, including the iliac, femoral, popliteal, tibial, mesenteric, and renal arteries. The product categories analyzed encompass metal stents, drug-eluting stents, drug-coated balloons, PTA balloons, and various catheters, which together represent the core components of the peripheral interventions market. The evaluation includes market performance from 2021 through 2024, along with detailed revenue forecasts through 2029, based on validated data derived from the Frost & Sullivan study 

Geographically, the analysis spans North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, each assessed individually to capture distinct adoption patterns and growth environments. The study incorporates both top-down and bottom-up models, using data sourced from company financials, regulatory databases, clinical trial results, healthcare expenditure trends, and expert interviews. Prevalence and diagnosis rates of PAD, reimbursement systems, and regional pricing variations form key pillars of the analytical framework.

The scope also accounts for pipeline developments, especially next-generation drug-eluting solutions and bioresorbable scaffold platforms, which are expected to significantly influence future revenue composition. While the study includes stents, balloons, and catheters, it excludes certain peripheral technologies such as atherectomy devices, thrombectomy systems, guidewires, and sheaths, in accordance with the Frost & Sullivan methodology. This ensures a focused and accurate assessment of the core device categories driving growth within the global peripheral vascular device market.

Market Segmentation Analysis: Peripheral Vascular Devices Market, Global, 2024–2029

The peripheral vascular devices market is segmented into six key product categories, each serving a specific therapeutic role across the treatment spectrum of peripheral artery disease (PAD). These segments differ widely in clinical application, technology sophistication, adoption rates, and regional penetration. The segmentation framework also highlights how advancements in drug delivery, scaffold design, and procedural efficiency are reshaping the overall peripheral interventions market and influencing physician device choice.

1. Metal Stents

Metal stents represent the foundational segment within the peripheral vascular device market, widely used across iliac, femoropopliteal, and renal artery interventions. This category includes:

• Self-expanding stents: ideal for dynamic or flexible anatomies such as the superficial femoral artery (SFA)
• Balloon-expandable stents: preferred for precise implantation in rigid or calcified segments
• Covered (endoprosthesis) and bare metal stents (BMS)

Key Characteristics

• Provide mechanical scaffolding to restore luminal patency
• Valued in cost-sensitive regions due to affordability
• Still preferred in lesions with insufficient long-term DES evidence

Market Role

Although declining in high-income regions due to the rise of drug-based alternatives, metal stents remain essential in emerging markets and continue to support a significant volume of the peripheral angioplasty market.

2. Bioresorbable Stents (Bioresorbable Scaffolds)

Bioresorbable stents (BRS) constitute the most advanced and innovation-driven segment. Unlike permanent metal stents, these scaffolds:

• Provide temporary mechanical support
• Deliver drug therapy (sirolimus or everolimus)
• Gradually dissolve within 24–36 months

Key Characteristics

• Reduce need for reintervention
• Enable natural vessel healing and long-term flexibility
• Highly valuable for below-the-knee and CLTI cases where younger patients require long-term vessel adaptability

Market Role

Although still in clinical trial phases in many regions, BRS systems represent the future of peripheral vascular interventions, and ongoing FDA IDE approvals are accelerating global adoption.

3. Drug-Eluting Stents (DES)

DES are treated as the gold-standard technology across many vascular territories due to their strong clinical outcomes and ability to significantly reduce restenosis.

Key Characteristics

• Stents coated with a slow-release drug (paclitaxel or sirolimus)
• Available in both metal-based and bioresorbable forms
• Ideal for long, complex, or restenosis-prone lesions

Market Role

The DES segment holds the largest revenue share of the peripheral vascular devices market due to:

• Superior long-term patency
• Improved safety and reliability
• Expanding evidence base

As drug-eluting platforms continue to outperform older BMS solutions, DES adoption will accelerate especially in regions transitioning to advanced endovascular therapies.

4. Drug-Coated Balloons (DCBs)

Drug-coated balloons are rapidly becoming one of the most influential categories in the peripheral interventions market due to their minimally invasive, non-implant nature.

Key Characteristics

• Deliver antiproliferative drugs directly to the vessel wall
• Leave no permanent implant behind
• Minimize inflammation and foreign body response
• Offer significant benefits in long lesions, in-stent restenosis, and BTK disease

Market Role

DCBs are reshaping the peripheral angioplasty market, especially after FDA’s updated safety reassessment for paclitaxel-coated devices. Growing interest in sirolimus-coated balloons is further accelerating adoption in Europe, India, and Asia-Pacific.

5. PTA Balloons (Percutaneous Transluminal Angioplasty Balloons)

PTA balloons are the backbone of all angioplasty-based PAD procedures and act as the first-line tool before stenting or drug delivery.

Key Characteristics

• Used to pre-dilate, remodel, or open narrowed arteries
• Available in high-pressure and specialty configurations
• Exclude drug-coated balloons
• Essential for lesion preparation prior to DES or DCB deployment

Market Role

PTA balloons maintain strong global demand due to:

• High procedural volume
• Safety and reliability
• Critical importance in vessel preparation

Their continued relevance ensures sustained growth within the peripheral angioplasty market.

6. Catheters (Diagnostic & Interventional)

The catheter segment includes guide catheters, support catheters, microcatheters, and specialty tools used across all peripheral vascular procedures.

Key Characteristics

• Enable lesion crossing, device delivery, and imaging
• Support complex anatomies
• Essential for both diagnostic angiography and therapeutic interventions

Market Role

This segment is increasingly influenced by innovations such as:

• Radial-to-peripheral (R2P) access platforms
• Torqueable microcatheters
• Dual-purpose angiography + angioplasty systems

Catheters are indispensable across the entire peripheral vascular interventions market and represent a steady, high-utilization product segment supporting every other device category.

Growth Drivers: Peripheral Vascular Devices Market, Global, 2024–2029

Growth Drivers – Peripheral Vascular Devices Market

1. Rising Global Prevalence of Peripheral Artery Disease (PAD)

The growing burden of PAD—driven by aging populations, diabetes, hypertension, obesity, and smoking—is generating sustained demand for minimally invasive vascular treatments. Underdiagnosis in emerging markets further expands the potential patient pool.

2. Shift Toward Minimally Invasive Endovascular Procedures

Clinical preference is rapidly shifting from open surgical approaches to endovascular interventions due to shorter recovery times, fewer complications, and strong procedural success rates. This trend directly strengthens demand within the peripheral interventions market.

3. Advancements in Drug-Delivery and Stent Technologies

Innovations such as sirolimus-based drug-coated balloons (DCBs), next-generation drug-eluting stents (DES), and bioresorbable scaffolds are improving long-term patency and reducing restenosis. These advanced devices are increasingly adopted for complex and below-the-knee lesions.

4. Expansion of Outpatient and Office-Based Vascular Centers (OBLs/ASCs)

The rise of cost-efficient outpatient vascular care—particularly in the U.S.—is increasing procedure volumes and accelerating device usage. Favorable reimbursement structures further support market expansion.

5. Growing Investments in Imaging, Navigation, and Vessel Preparation Tools

Technologies such as intravascular ultrasound (IVUS), optical coherence tomography (OCT), intravascular lithotripsy (IVL), and high-pressure/scoring balloons are enhancing procedural precision, boosting usage of complementary devices across the peripheral angioplasty market.

6. Improving Access to Vascular Specialists in Emerging Markets

Countries such as India, China, Southeast Asia, and Brazil are witnessing increased availability of vascular surgeons and interventional radiologists, along with stronger insurance coverage and screening programs—supporting faster adoption of PAD devices.

7. Regulatory Support and Strong Clinical Evidence Base

Regulatory clarity—such as the FDA’s updated assessment of paclitaxel device safety—and expanding real-world evidence for DES/DCBs are improving clinician confidence and accelerating market penetration globally.

Growth Restraints: Peripheral Vascular Devices Market, Global, 2024–2029

1. Availability of Multiple Disease Management Alternatives

Depending on the patient’s condition, peripheral artery disease can often be managed through lifestyle modification, medications, supervised exercise therapy, drug-coated balloons, bypass surgery, or other peripheral stent options. The wide availability of alternative treatment pathways limits growth potential for certain device categories, particularly in early-stage PAD cases.
2. Slow Growth in Bare Metal Stents Due to Advanced Drug-Eluting Solutions

The continued emergence of next-generation drug-eluting stents and drug-based vessel-preserving technologies has reduced clinical preference for traditional bare metal stents. This shift slows revenue growth in legacy product categories within the peripheral vascular devices market.
3. Low PAD Awareness and Limited Screening in Primary Care

Peripheral artery disease remains significantly underdiagnosed due to low awareness among patients and limited screening practices in primary care settings. Delayed diagnosis reduces the number of patients eligible for timely intervention, moderating growth across the peripheral interventions market.
4. High R&D Costs and Stringent Regulatory Requirements

Advanced peripheral vascular devices, especially DES, DCBs, IVL systems, and bioresorbable scaffolds—require extensive R&D investment and long clinical trial timelines to meet stringent regional regulatory standards. These barriers slow innovation speed and restrict the near-term commercialization of emerging technologies.

Competitive Landscape: Peripheral Vascular Devices Market, Global, 2024–2029

The peripheral vascular devices market is moderately concentrated, with the top six manufacturers accounting for approximately 75% of global revenues in 2024, according to Frost & Sullivan 

Competition is driven by technological innovation, product performance, clinical outcomes, regulatory status, and regional expansion strategies.

Boston Scientific leads the global market with a 27.4% revenue share, supported by a diverse portfolio that includes the Eluvia drug-eluting stent, Ranger drug-coated balloon, Mustang and Coyote PTA balloons, and the Innova and Epic self-expanding stent systems. The company’s recent acquisition of Acotec Medical and advancements in large clinical registries position it strongly for continued expansion in both developed and emerging markets.

Abbott holds a substantial market share with a focus on next-generation drug-eluting technologies and bioresorbable scaffolds. Its SurVeil drug-coated balloon, Supera stent system, and the FDA-approved Esprit BTK resorbable scaffold represent significant advancements in CLTI management. Long-term data demonstrating improved patient outcomes have enhanced Abbott’s competitive position, particularly in the BTK segment where demand for innovative solutions continues to grow.

Medtronic remains a major player with a broad vascular portfolio that includes the EverFlex stent, IN.PACT Admiral and IN.PACT AV drug-coated balloons, and Visi-Pro balloon-expandable stents. Strategic distribution agreements and ongoing clinical evaluations strengthen its foothold in the peripheral interventions market.

BD (Bard) focuses heavily on PTA balloons and covered stent platforms, with its Lutonix drug-coated balloon and LifeStent vascular systems forming the core of its product offerings. Ongoing IDE studies are expected to validate additional indications and increase clinical adoption.

Terumo has emerged as a leader in radial-to-peripheral procedural solutions, offering products such as the MISAGO self-expanding stent and the R2P NaviCross support catheter. Its strategic emphasis on radial access gives it a unique advantage in procedural innovation.

Other important competitors include MicroPort Scientific, Biotronik, iVascular, Getinge, Veryan Medical, Meril Life Sciences, and Cordis, all of which contribute to a dynamic and rapidly evolving competitive ecosystem. This competitive intensity is expected to increase as advancements in sirolimus-based DCBs, resorbable scaffolds, microcatheter innovations, and robotics reshape future market dynamics.